IO Biotech (IOBT) announced that it has retained Raymond James & Associates to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the company explores strategic alternatives.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT:
- Midday Fly By: Minnesota CEOs call for deescalation, Nvidia invests in CoreWeave
- Piper downgrades IO Biotech amid strategic alternatives evaluation
- IO Biotech downgraded to Neutral from Overweight at Piper Sandler
- IO Biotech Explores Strategic Alternatives Amid Cost-Cutting Plans
- IO Biotech announces exploration of strategic alternatives